Skip to content

Treatment-resistant depression

TL;DR — TRD usually means failure to respond to at least two adequate antidepressant trials, but “adequate,” response, adherence, and diagnostic certainty vary, making prevalence and comparative evidence unstable (Gaynes 2020, PMID 31638723; Sforzini 2022, PMID 34907394). Before escalating, clinicians must distinguish true resistance from bipolarity, psychosis, substance/medical causes, nonadherence, intolerable exposure, inadequate dose/duration, and persistent psychosocial drivers. Evidence supports switching, antidepressant combinations, lithium or second-generation antipsychotic augmentation, ketamine/esketamine, ECT, and TMS, but head-to-head sequencing data are sparse. STAR*D showed diminishing remission across steps, yet its cumulative 67% estimate is disputed (Rush 2006, PMID 17074942; Pigott 2023, PMID 37491091).

Definition

Element Minimum operational question
Diagnosis Is this unipolar MDD, and is the current episode active?
Trial count Have at least two treatments failed?
Adequacy Was dose, duration, and adherence sufficient?
Outcome Nonresponse, partial response, intolerance, or relapse?
Stage Same episode; number and type of mechanisms tried

Consensus recommends a reproducible trial definition including confirmed MDD, prospective outcome measurement, and documented adequacy (Sforzini 2022, PMID 34907394). “Difficult-to-treat depression” can be more clinically honest when multiple biological, psychological, and social factors sustain illness (McAllister-Williams 2020, PMID 32217227).

Pseudo-resistance checklist

Source Examples Corrective action
Diagnostic bipolar disorder, psychotic depression, PTSD, substance-induced longitudinal reassessment
Treatment low dose, short exposure, poor adherence reconstruct actual exposure
Medical sleep apnea, endocrine/neurological disease, pain targeted evaluation
Outcome scale improvement without functional recovery measure symptoms and function
Context violence, housing insecurity, ongoing loss address sustaining exposure

Sequenced evidence

STAR*D step remission decreased from 36.8% at step 1 to 13.0% at step 4 and relapse increased among those requiring more steps (Rush 2006, PMID 17074942). A protocol-faithful reanalysis reported lower estimates and criticized denominators and outcome substitutions (Pigott 2023, PMID 37491091). The robust conclusion is declining yield and worsening prognosis with successive failures; the exact cumulative figure remains contested.

Strategy map

Strategy Evidence Principal tradeoff
Optimize/current drug appropriate when partial response and tolerability delays mechanism change
Switch antidepressant common, limited evidence of one best switch loses partial benefit
Combine antidepressants meta-analytic benefit in selected combinations interaction/AE burden (Henssler 2022, PMID 35171215)
Lithium augmentation established evidence, possible anti-suicidal value renal/thyroid monitoring, toxicity
SGA augmentation several approved agents akathisia, metabolic and tardive risks
Esketamine/ketamine rapid effect monitoring, durability, access
TMS non-systemic and effective daily course, access
ECT strongest acute option for severe/urgent disease anesthesia, cognitive effects, relapse prevention

Network meta-analysis supports several augmentation strategies but comparisons are indirect and short-term (Nuñez 2022, PMID 34986373). A separate synthesis of early-stage resistance finds benefits across augmentation and combination options with heterogeneous certainty (Scott 2023, PMID 35861202). Comparative review of antipsychotics, esketamine, and lithium does not establish one universally superior sequence (Vázquez 2021, PMID 34238049).

Rapid and device-based escalation

Esketamine plus oral antidepressant improved resistant depression in acute trials and delayed relapse among responders (Popova 2019, PMID 31109201; Daly 2019, PMID 31166571). In nonpsychotic TRD, ketamine was noninferior to ECT on the primary response outcome in ELEKT-D, while ECT remains favored when psychosis, catatonia, or immediate severity makes maximal established efficacy decisive (Anand 2023, PMID 37224232).

Outcomes beyond response

Remission, function, cognition, suicidality, treatment burden, and durability should be reported separately. A rapid symptom reduction that requires indefinite high-burden maintenance is different from sustained functional recovery.

What “resistance” contains

Apparent TRD combines true nonresponse with inadequate dose/duration, nonadherence, intolerability, misdiagnosis, comorbidity, and an outcome measure that may ignore meaningful functional gain. Published definitions remain inconsistent.

Decision point Comparative evidence Limitation
Switch or augment after one failure Pragmatic VAST-D and OPTIMUM data favor augmentation in some populations Older veterans and geriatric cohorts are not interchangeable with all adults
Which augmenter? Network syntheses support several atypical antipsychotics and lithium Short trials and adverse-event undermeasurement weaken rankings
Add psychotherapy? Randomized evidence supports psychological treatment after pharmacologic nonresponse Access and therapist expertise determine feasibility
Escalate to device/rapid-acting treatment? ECT, TMS, and ketamine show efficacy Few direct head-to-head sequence trials exist
Define success by remission? Remission predicts better prognosis Function, cognition, relationships, and treatment burden may lag

TRD prevalence depends directly on the adequacy rule and denominator. A reproducible staging system should state failed mechanism, dose, duration, adherence, tolerability, psychotherapy exposure, and longitudinal diagnosis.

Additional live-search evidence ledger

The records below were added after full PubMed E-utilities retrieval on 2026-08-30. The ledger states the evidentiary role of each record and preserves the design limitation that should travel with its citation.

  • Cai L 2024 — miRNAs in treatment-resistant depression: a systematic review. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Cai L 2024, PMID 38727891)

  • Hannah LA 2023 — Economic evaluation of interventions for treatment-resistant depression: A systematic review. Systematic review; useful for mapping consistency and gaps, not automatically a pooled causal estimate. (Hannah LA 2023, PMID 36873195)

  • Terao I 2024 — Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Terao I 2024, PMID 37949235)

  • Strawbridge R 2019 — Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Strawbridge R 2019, PMID 30457075)

  • Bauer M 1999 — Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Bauer M 1999, PMID 10505584)

  • Zhou X 2015 — Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Zhou X 2015, PMID 25919841)

  • Hsu TW 2026 — Reappraising lithium, triiodothyronine and second-generation antipsychotic augmentation treatment for major depression: a systematic review and meta-analysis with bias-adjustment analyses. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Hsu TW 2026, PMID 42532626)

  • Austin MP 1991 — Lithium augmentation in antidepressant-resistant patients. A quantitative analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Austin MP 1991, PMID 1836411)

  • Nelson JC 2014 — A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Nelson JC 2014, PMID 25069082)

  • Bauer M 2003 — Lithium augmentation therapy in refractory depression-update 2002. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Bauer M 2003, PMID 12904977)

  • Bauer M 2014 — Role of lithium augmentation in the management of major depressive disorder. Primary or secondary empirical evidence; interpretation should follow its design and comparator rather than the headline alone. (Bauer M 2014, PMID 24590663)

  • Eckert D 2026 — Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Eckert D 2026, PMID 41572784)

  • Wang J 2023 — Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Wang J 2023, PMID 37746943)

  • Yan Y 2022 — Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Meta-analysis; pooled estimates depend on eligibility, heterogeneity, and reporting bias. (Yan Y 2022, PMID 35993319)

  • Mohamed S 2017 — Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Mohamed S 2017, PMID 28697253)

  • Zisook S 2019 — General Predictors and Moderators of Depression Remission: A VAST-D Report. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Zisook S 2019, PMID 30947531)

  • Mohamed S 2020 — Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Mohamed S 2020, PMID 32603560)

  • Yoon J 2018 — Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. Randomized comparison; population, control credibility, duration, and missingness bound transportability. (Yoon J 2018, PMID 30695291)

Open questions

  • Which uniform adequacy criteria produce comparable TRD trials (Sforzini 2022, PMID 34907394)?
  • What is the optimal head-to-head sequence among lithium, SGA augmentation, TMS, esketamine, and ECT?
  • Which partial responders should augment rather than switch (Nuñez 2022, PMID 34986373)?
  • How should social and comorbidity-driven difficult-to-treat depression be represented in staging?

References

  1. Gaynes BN, et al. Defining treatment-resistant depression. Depression and Anxiety. 2020. PMID 31638723
  2. Sforzini L, et al. Consensus guideline for definition of TRD for clinical trials. Molecular Psychiatry. 2022. PMID 34907394
  3. McAllister-Williams RH, et al. Difficult-to-treat depression: international consensus statement. Journal of Affective Disorders. 2020. PMID 32217227
  4. Rush AJ, et al. STAR*D outcomes. American Journal of Psychiatry. 2006. PMID 17074942
  5. Pigott HE, et al. Reanalysis of STAR*D. BMJ Open. 2023. PMID 37491091
  6. Nuñez NA, et al. Augmentation strategies for treatment-resistant major depression. Journal of Affective Disorders. 2022. PMID 34986373
  7. Scott F, et al. Augmentation and combination treatments for early-stage TRD. Journal of Psychopharmacology. 2023. PMID 35861202
  8. Vázquez GH, et al. Antipsychotics vs esketamine vs lithium combinations. Journal of Psychopharmacology. 2021. PMID 34238049
  9. Popova V, et al. Esketamine nasal spray in TRD. American Journal of Psychiatry. 2019. PMID 31109201
  10. Daly EJ, et al. Esketamine relapse prevention. JAMA Psychiatry. 2019. PMID 31166571
  11. Anand A, et al. Ketamine versus ECT for nonpsychotic TRD. New England Journal of Medicine. 2023. PMID 37224232
  12. Henssler J, et al. Combining antidepressants versus monotherapy. JAMA Psychiatry. 2022. PMID 35171215
  13. Cai L, et al. miRNAs in treatment-resistant depression: a systematic review. Molecular biology reports. 2024;51:638. PMID 38727891
  14. Hannah LA, et al. Economic evaluation of interventions for treatment-resistant depression: A systematic review. Frontiers in psychiatry. 2023;14:1056210. PMID 36873195
  15. Terao I, et al. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis. Journal of affective disorders. 2024;346:49-56. PMID 37949235
  16. Strawbridge R, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. The British journal of psychiatry : the journal of mental science. 2019;214:42-51. PMID 30457075
  17. Bauer M, et al. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. Journal of clinical psychopharmacology. 1999;19:427-34. PMID 10505584
  18. Zhou X, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. The Journal of clinical psychiatry. 2015;76:e487-98. PMID 25919841
  19. Hsu TW, et al. Reappraising lithium, triiodothyronine and second-generation antipsychotic augmentation treatment for major depression: a systematic review and meta-analysis with bias-adjustment analyses. BMJ mental health. 2026;29:e302656. PMID 42532626
  20. Austin MP, et al. Lithium augmentation in antidepressant-resistant patients. A quantitative analysis. The British journal of psychiatry : the journal of mental science. 1991;159:510-4. PMID 1836411
  21. Nelson JC, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Journal of affective disorders. 2014;168:269-75. PMID 25069082
  22. Bauer M, et al. Lithium augmentation therapy in refractory depression-update 2002. European archives of psychiatry and clinical neuroscience. 2003;253:132-9. PMID 12904977
  23. Bauer M, et al. Role of lithium augmentation in the management of major depressive disorder. CNS drugs. 2014;28:331-42. PMID 24590663
  24. Eckert D, et al. Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2026;27:200-211. PMID 41572784
  25. Wang J, et al. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis. Medicine. 2023;102:e34670. PMID 37746943
  26. Yan Y, et al. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychological medicine. 2022;52:2224-2231. PMID 35993319
  27. Mohamed S, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017;318:132-145. PMID 28697253
  28. Zisook S, et al. General Predictors and Moderators of Depression Remission: A VAST-D Report. The American journal of psychiatry. 2019;176:348-357. PMID 30947531
  29. Mohamed S, et al. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal of clinical psychiatry. 2020;81:19m13038. PMID 32603560
  30. Yoon J, et al. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal of clinical psychiatry. 2018;80:18m12294. PMID 30695291